Daniel Bouch, The Ohio State University, Columbus, Ohio
Optimizing virus-based delivery of CMT gene therapies
Daniel Bouch is engineering next-generation viral vectors, called adeno-associated viruses, to deliver gene therapies directly to Schwann cells. Schwann cells are critical for producing myelin and maintaining peripheral nerve function. His project, under the guidance of Dr. Afrooz Rashnonejad, aims to overcome the major challenge of crossing the blood-nerve barrier to efficiently reach Schwann cells. Using a “Key-Switch” system, his team will generate a library of AAVs displaying different surface “keys,” each with a “switch” that activates only when the virus successfully reaches Schwann cells. This approach allows the researchers to identify which “keys” most effectively target Schwann cells and understand the biological pathways — or “locks” — that enable delivery across the blood-nerve barrier. By optimizing these delivery vehicles, the project could improve gene therapy strategies for demyelinating forms of CMT and inform future approaches for targeted nerve repair.
I’m incredibly honored to receive the CMTRF Emerging Researcher Award. As a scientist, my goal is to make a meaningful impact, and I believe this project addresses one of the key obstacles standing in the way of effective gene therapies for Charcot-Marie-Tooth disease. Thanks to the generosity of CMTRF, I’m empowered to continue developing therapies that bring real hope to patients and families affected by CMT.
